AAP
REPL icon

Arax Advisory Partners’s Replimune Group REPL Stock Holding History

Arax Advisory Partners’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19
Closed -$185 – 4233
2025
Q4 		$185 Sell
19
-304
-94% -$2.58K ﹤0.01% 3735
2025
Q3 		$1.35K Buy
+323
New +$2.06K ﹤0.01% 3192

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arax Advisory Partners's REPL Position: Q1 2026 in Review

Arax Advisory Partners sold out of Replimune Group (REPL) in Q1 2026, closing a stake of 19 shares — an estimated $185 sold.

Arax Advisory Partners first reported a position in REPL in Q3 2025 and held it in 2 quarters. The position peaked at $1.35K in Q3 2025. 180 funds tracked by Wall St. Rank hold REPL as of Q1 2026.

  • Arax Advisory Partners reported no remaining Replimune Group position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 19 Replimune Group shares in Q1 2026, an estimated $185.
  • Arax Advisory Partners first reported a position in Replimune Group in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Replimune Group position peaked at $1.35K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Replimune Group as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.